Evidence Gaps

Silodosin vs placebo

Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1743 participants
Low

Silodosin vs naftopidil

Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 652 participants
Low

Silodosin vs alfuzosin

Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
Low

Silodosin vs tamsulosin

Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 1708 participants
Low

Naftopidil vs silodosin (alpha‐blocker)